NIVABUPA - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.6
| Stock Code | NIVABUPA | Market Cap | 15,909 Cr. | Current Price | 86.0 ₹ | High / Low | 94.0 ₹ |
| Stock P/E | 122 | Book Value | 20.5 ₹ | Dividend Yield | 0.00 % | ROCE | 3.45 % |
| ROE | 3.82 % | Face Value | 10.0 ₹ | DMA 50 | 78.2 ₹ | DMA 200 | 77.5 ₹ |
| Chg in FII Hold | 0.29 % | Chg in DII Hold | 0.45 % | PAT Qtr | 345 Cr. | PAT Prev Qtr | -87.6 Cr. |
| RSI | 69.3 | MACD | 1.88 | Volume | 61,83,271 | Avg Vol 1Wk | 28,86,350 |
| Low price | 67.5 ₹ | High price | 94.0 ₹ | PEG Ratio | 0.95 | Debt to equity | 0.07 |
| 52w Index | 69.8 % | Qtr Profit Var | 67.5 % | EPS | 0.71 ₹ | Industry PE | 42.8 |
📊 Financials: The company shows weak profitability with ROE at 3.82% and ROCE at 3.45%, reflecting limited efficiency in capital usage. Debt-to-equity is low at 0.07, indicating a healthy balance sheet. Quarterly PAT improved significantly from -₹87.6 Cr. to ₹345 Cr., highlighting a turnaround in earnings. EPS of ₹0.71 remains modest, suggesting limited cash flow strength.
💹 Valuation: Current P/E of 122 is extremely high compared to the industry average of 42.8, suggesting severe overvaluation. The PEG ratio of 0.95 indicates growth prospects are somewhat aligned with price. Book value of ₹20.5 against a market price of ₹86.0 implies a stretched P/B ratio. Intrinsic value appears lower than current levels, requiring caution.
🏭 Business Model: The company operates in health insurance, benefiting from rising demand for healthcare coverage and government initiatives. Competitive advantage lies in brand recognition and expanding customer base, though profitability remains weak and valuations stretched.
📈 Entry Zone: A favorable entry would be closer to ₹75–80, near the 50 DMA of ₹78.2 and 200 DMA of ₹77.5. Current price of ₹86.0 is above fair value, so accumulation on dips is recommended.
⏳ Long-Term Holding: While the company benefits from sectoral demand and recent profitability improvement, weak return ratios and stretched valuations make long-term holding risky. Investors should wait for consistent earnings before aggressive accumulation.
Positive
- ✅ PAT turnaround from -₹87.6 Cr. to ₹345 Cr.
- ✅ Low debt-to-equity ratio (0.07)
- ✅ Increase in FII (+0.29%) and DII (+0.45%) holdings shows institutional support
Limitation
- ⚠️ Very high P/E (122) compared to industry average
- ⚠️ Weak ROE (3.82%) and ROCE (3.45%)
- ⚠️ EPS of ₹0.71 highlights limited profitability
Company Negative News
- 📉 Historically weak profitability despite recent PAT improvement
Company Positive News
- 📈 PAT turnaround highlights operational recovery
- 📈 Increase in institutional holdings reflects investor confidence
Industry
- 🏥 Health insurance sector benefits from rising healthcare demand
- 📊 Industry P/E at 42.8 suggests peers are valued lower
- 🌍 Growth opportunities in expanding coverage and government-backed schemes
Conclusion
Overall, the company has shown a strong turnaround in profitability and enjoys sectoral demand tailwinds. However, weak return ratios and extreme valuations limit attractiveness. Best strategy is cautious accumulation near ₹75–80 for long-term holding, while waiting for consistent earnings improvement before aggressive buying.
Would you like me to extend this with a peer comparison against other health insurance companies, or a technical analysis view to highlight support/resistance and momentum indicators?